KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Amortization - Deferred Charges (2016 - 2017)

Emergent BioSolutions (EBS) has 3 years of Amortization - Deferred Charges data on record, last reported at $96000.0 in Q4 2017.

  • For Q4 2017, Amortization - Deferred Charges fell 54.72% year-over-year to $96000.0; the TTM value through Dec 2017 reached $681000.0, down 13.36%, while the annual FY2017 figure was $681000.0, 12.8% down from the prior year.
  • Amortization - Deferred Charges reached $96000.0 in Q4 2017 per EBS's latest filing, down from $195000.0 in the prior quarter.
  • Across five years, Amortization - Deferred Charges topped out at $215000.0 in Q1 2016 and bottomed at $96000.0 in Q4 2017.
  • Average Amortization - Deferred Charges over 3 years is $184888.9, with a median of $195000.0 recorded in 2017.
  • The widest YoY moves for Amortization - Deferred Charges: up 10.8% in 2017, down 54.72% in 2017.
  • A 3-year view of Amortization - Deferred Charges shows it stood at $197000.0 in 2015, then grew by 7.61% to $212000.0 in 2016, then crashed by 54.72% to $96000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Amortization - Deferred Charges were $96000.0 in Q4 2017, $195000.0 in Q3 2017, and $195000.0 in Q2 2017.